• Janset Özdemir
  • Mert Yücel
  • Sarper Kızılkaya
  • Gizem Yıldırım
  • Irmak İrem Özyiğit
  • Zerrin Yuluğkural

Received Date: 20.01.2022 Accepted Date: 06.06.2022 Turk Med Stud J 2022;9(2):48-54

Human papillomavirus is the most common sexually transmitted viral infection in the world. The infection can cause cancers of the anus, vulva, vagina, penis, and oropharynx. There are more than one hundred subtypes of human papillomavirus, of which thirteen are the high-risk types that may cause cancer. Human papillomavirus 16 and 18 are the main types that are noted as high-risk, causing cancer and neoplasia. Cervical cancer is the fourth most frequent cancer among women worldwide, yet it is preventable and treatable when diagnosed early. Almost all cervical cancer cases are linked to infection with high-risk human papillomavirus subtypes, which are extremely common. Cervical cancer occupies a large place in cancer screening, diagnosis, and treatment. It is critical to include the vaccine in national vaccination programs in order to increase herd immunity to human papillomavirus. The human papillomavirus vaccine should be made accessible to everyone, as well as screening tests for human papillomavirusrelated diseases. The awareness of human papillomavirus vaccines in immunization programs by health authorities can significantly increase the acceptability of the vaccine in communities. As of May 2022, the human papillomavirus vaccine is not included in the national vaccination program in Turkey. In our study, we have compiled why the human papillomavirus vaccine should be included in the vaccination calendar in Turkey, within the scope of the latest research on this subject.

Keywords: Cervical cancer, vaccination, human papillomavirus, viral infection, public health


Human papillomavirus (HPV) is a group of viruses that are common all over the world. There are more than one hundred subtypes of HPV, of which 13 are high-risk subtypes that can cause cancers of the epithelial mucosal surfaces (1). There is evidence that HPV causes cancers of the anus, vulva, vagina, penis, oropharynx, and cervix (2). Cervical cancers are the fourth most common type of cancer encountered in women worldwide (3). Two types of HPV (HPV16 and 18) are known to cause 70% of cervical cancers and pre-cancerous lesions (3).

Human papillomavirus is transmitted through sexual contact or mucosal contact with an infected area (1). Various methods such as condom use, avoidance of direct contact, testing, and vaccination can be used to prevent the spread of HPV and the risk of cancer (2). Most countries have included the HPV vaccine in their vaccination calendar in order to reduce the economic burden of HPV (4). In our study, we presented general information on HPV and its vaccination, and have compiled why the HPV vaccine should be included in the vaccination calendar in Turkey, within the scope of the latest research on this subject.


Human papillomavirus related diseases are the most common sexually transmitted viral infections in the world. It is accepted that most sexually active people are infected with at least one type of HPV at some point in their lives (5-7). The peak prevalence of HPV among young women is at the ages of 20 to 24 (8). However, the prevalence of HPV remains steady among men in all age groups (9, 10). In addition to cervical, penile, anal, vaginal, vulvar, and oropharyngeal cancers, HPV is associated with respiratory papillomatosis and anogenital warts (7). According to a systematic review of thirty-two studies conducted around the world, the annual incidence of anogenital warts ranged from 160 to 289 cases per 100,000 (11). The infection is transmitted through close skin-to-skin contact, most commonly through sexual contact (7). It can be transmitted by skin-mucous contact to the genital areas of the infected area of the person, such as the penis or female external genitalia, or areas such as the mouth and anus (7). Moreover, autoinoculation can occur from one part of the body to another (12).

Eighty-four percent of new cervical cancer cases and 90% of mortalities occur in middle- and low-income countries (13). Almost all cervical cancer cases are linked to infection with high-risk HPV (3). According to the World Health Organization (WHO), cervical cancer was diagnosed in around 570,000 women worldwide in 2018 and about 311,000 women died from the disease (3, 14). While the incidence of cervical cancer is relatively high in Central and Eastern European countries, around 14.9 cases per 100,000, it is lower in Western European countries with 6.9 cases per 100,000 (15). Turkey, on the other hand, has an age-adjusted incidence, which is 4.3 per 100,000 and its mortality is 1.7 per 100,000 (16). In addition, HPV16 and HPV18 are responsible for 75.4% of HPV-positive invasive cervical cancer cases in Turkey (17).


Human papillomavirus, a non-enveloped capsid virus with double-stranded DNA, enters the human body through cracks in the epidermis (18). Chronic infection, local infection, or dysplasia are degenerative changes that occur before malignancy (19). Regardless of gender, HPV can cause conditions and diseases in humans (20). HPV exposure can cause benign warts and cancers, though having no evident disease is more common (21). The immune system can recognize HPV and cure HPV infection (7). Therefore, HPV does not lead to the aforementioned conditions every time (7). In some cases, HPV was cleared from the body within two years (22). However, in organ-transplant and immunosuppressed patients, HPV-related diseases present themselves more frequently (e.g., anal cancer ratio of HIV-infected men is greater than HIV-negative men) and more complex due to widespread clinical presentations, creating a much larger burden (7, 23).

HPV-associated Cancers

Human papillomavirus is known to cause two main types of cancer: mucosal and skin (24). HPV is as a risk factor for oropharyngeal, anal, penile, and cervical cancers (25, 26). Benign lesions are more frequent even though high-risk types can also be detected in the head area, such as squamous cell carcinoma being the most common cancer of the oral cavity (27). HPV causes cervical cancers more commonly, though penile cancer rates of 20-60% are not negligible (28).

Cervical cancer is the only one that was admitted to the routine screening among HPV-associated cancers (3, 29). Especially HPV16 and 18 variants have a strong relationship with cervical cancer (19, 22, 30). It is estimated that 96% of cervical cancers are due to HPV (24). After the initial HPV exposure, precancerous lesions followed by cervical invasion create cervical cancer (29). The primary risk factor for cervical cancer is the male partner’s sexual behavior (29).


There is no generally accepted treatment for symptomatic HPV infection, though clinical studies continue to overcome this gap (31). Gene-Eden-VIR/Novirin is among those studies and achieved decreased time for HPV clearance with no adverse effect in one of its clinical trials (31).

Genital warts tend to regress by themselves with or without treatment due to their benign nature (7). Treatment of genital warts includes topical medications (podofilox gel, imiquimod cream, sinecatechins ointment) and only avails presenting symptoms (7, 32). Cryotherapy is another method to deal with warts, but, for widespread cases, surgical approaches are recommended (7, 32).

Radiotherapy, chemotherapy, and surgical removal of the infected tissues/organs are alternatives to manage to treat HPV-related cancers (33). For cervical cancer, different outcomes can be obtained depending on cancer staging, and it is easier to achieve complete resolution in stage 1A, while palliative care is the only option in stage 4B (21, 32). The desire for fertility, size of the tumor, and age of the patient may also affect the treatment plan of cervical cancer (7). Cisplatin is the primary option for chemotherapy, and cetuximab-based treatment could be an alternative for it (21, 34).

Notably, there are studies on therapeutic vaccines aiming to target HPV proteins and create an immune response without needing any further surgeries (35). However, there are still obstacles ahead, and currently, there is no approved therapeutic vaccine in use (35). Targeting E6 and E7 oncoproteins is in development for anal cancer besides many other epithelial neoplasms (36). Also, for penile cancer, studies targeting the HPV pathway with T-cell therapy in addition to chemotherapy are ongoing (28).


Vaccines came into use mainly in the 20th century, and their impact on public health and mortality reduction was enormous (37). In general, elimination studies are carried out with vaccines against fourteen main diseases worldwide (38). A standardized vaccination scheme that focused on child vaccination was established within the scope of the Expanded Programme on Immunization (EPI) implemented by WHO in 1977 (38). This scheme has been expanded for different diseases in accordance with endemic countries and developing technology (38). Countries also have immunization programs associated with EPI and these vary depending on regional and country policies. Moreover, the HPV vaccine is included in vaccination programs in some countries (38).

Human papillomavirus vaccines are used for recognizing the natural immunity toward L1 capsid protein and providing antibody protection (39). The vaccines include L1 major capsid proteins that resemble HPV particles (38). There are three licensed vaccines against disease-causing HPVs: divalent Cervarix (HPV16 and 18), a tetravalent Gardasil (HPV6, 11, 16, and 18), and a nine-valent Gardasil 9 (HPV6, 11, 16, 18, 31, 33, 45, 52, and 58) (38, 40). All three contain the two high-risk HPV subtypes (HPV16 and 18). Furthermore, Gardasil prevents infections of HPV6 and 11, which are responsible for 90% of genital warts, and Gardasil 9 inhibits five more HPV subtypes that are responsible for 10% to 20% of cervical cancers (40). HPV vaccines are projected to be a profitable option primarily to reduce the incidence of cervical cancer and anogenital HPV infections (41).

World Health Organization aims to vaccinate 90% of all girls by the age of 15 years, to screen 70% of women aged 35-45 years twice, to ensure that at least 90% of all precancerous lesions detected during screening are cured. Thus, it aims to reduce the age-specific incidence of cervical cancer to less than 4 per 100,000 women worldwide (42). American Cancer Society recommends HPV vaccinations to girls and boys aged 9-14 years and young male adults and suggests HPV vaccines for young female adults aged 14-26 years to be recommended by consulting with healthcare professionals and making a clinical decision after the risks are understood. WHO does not recommend HPV vaccination primarily to males and argues that priority should be given to females at risk of cervical cancer. However, the Centers for Disease Control and Prevention (CDC) suggest the Gardasil vaccine for young males (40). In addition, WHO does not recommend HPV vaccination during pregnancy, especially considering the risk of spontaneous abortion (43).

Global Policies

Human papillomavirus infection constitutes approximately 2% of the total cancer burden in more developed countries and almost 7% in less developed countries (38). Different policies are followed regarding HPV vaccination around the world. HPV vaccines for girls are on the vaccination schedule in forty-five countries, mostly in Europe (38). These HPV vaccines on the vaccination schedule are covered by various insurance systems of the countries (38). Besides, there are licensed HPV vaccines in more than a hundred countries (40). The thirty countries that are a part of the European Economic Area all had the HPV vaccination introduced in their national vaccination programs, except for Romania where it was introduced in 2008 but discontinued after low rates of public acceptance (44, 45). Three HPV vaccines have been licensed in Europe: bivalent, quadrivalent, and nonavalent, publicly known and marketed as Cervarix, Gardasil 4 or Silgard, and Gardasil 9, respectively (46). Poland is the sole country in the European Union that requires full out-of-pocket payment for HPV vaccination (45). In Slovakia, the amount of required payment varies between the types of licensed HPV vaccines (45). In other countries, vaccination is provided free of charge (44). In the United States of America, the Vaccines for Children program funded by the federal government is the main way for children who otherwise do not have access to vaccines, to receive HPV vaccination (47). Although the program provides vaccines at no cost, it only covers children under 18 years of age who are uninsured, Medicaid-eligible, a program that provides health coverage to low-income American citizens, or American Indian/Alaska Native (47, 48). Even though the vaccination can be started at the age of 9 years, the CDC recommended age is 11-12 years (47). The nonavalent vaccine (Gardasil 9) is the only HPV vaccine currently authorized by the federal United States government (49). In Latin America where 64,000 new cases of cervical cancer and 26,000 deaths from it were reported each year, nine countries remain to have introduced the HPV vaccine as of December 2016 (Costa Rica, Cuba, Dominican Republic, El Salvador, Haiti, Guatemala, Martinique, Nicaragua, and Venezuela) (50). China has no HPV vaccination program (51). Bivalent HPV (Cervarix), quadrivalent HPV (Gardasil), and nonavalent HPV (Gardasil 9) are all licensed in China, but they are reported to be expensive and in limited supply (51). In India, similar to China, despite the recommendation by the National Technical Advisory Group on Immunization an HPV vaccination program has not been implemented as of 2018 (52). As of June 2019, nine Sub-Saharan African countries have included HPV vaccination in their National Immunization Programs: Botswana, Lesotho, Rwanda, Sao Tome and Principe, Senegal, Seychelles, South Africa, Uganda, Mauritius, and twenty-two additional countries have HPV vaccine demonstration projects in motion (53). Both of these statistics are in a prime position to increase considerably as international organizations such as the Global Alliance for Vaccines and Immunization and the Program for Appropriate Technology in Health, along with the WHO and United Nations Children’s Fund, have generated substantial momentum around HPV vaccination in Sub-Saharan African countries (54).

Global Awareness and Acceptability

Even though its effectiveness is debated, increasing the knowledge of HPV is suggested as one of the methods to improve HPV vaccine uptake (55). Awareness and acceptability of HPV vaccination have been major factors in the success of individual countries’ vaccination programs, one example of this being the Romanian HPV vaccination program falling out due to a low level of public acceptance (44). A major part of the public perception of HPV vaccination is the view of parents (55). Parents of adolescents who had no intention of having their children vaccinated in a 12-month window expressed their reasoning as their child not being at a proper age for vaccination while closely associating it with the age of sexual activity (56).

The emergence of social media and the transition of a new generation into adulthood has shown the potential to positively affect awareness of HPV (57, 58). Although social media creates a more comfortable environment for sharing knowledge on HPV and enables the general public to engage with more information, social media can be used to spread negative content as well (58). Positive content on social media about HPV and HPV vaccination was reported to be associated with greater vaccine coverage, and the negative content on it had adverse effects on its public perception (58). With these in mind, it is important to note that positive content about HPV was able to reach larger audiences compared to its negative counterpart (57, 58).

Evaluation of the Current Status of Turkey

World Health Organization recommends nationwide screening of cervical cancer in all countries (38). According to the national cancer screening standards in Turkey; every woman between 30 to 65 years of age should be screened with HPV-DNA and Pap smear test every five years (38). Screenings are carried out free of charge at Cancer Early Diagnosis, Screening and Training Centers, Family Health Centers, Community Health Centers, and Healthy Life Centers (38). WHO recommends the administration of two doses of vaccination to girls, 6-12 months apart, before sexual intercourse (between 9-14 years of age) (38). However, HPV vaccines are not included in any vaccination program in Turkey. There are two main interventions in the country’s policies in the fight against cervical cancer in general (59). First of which screening tests are developed for early diagnosis as a secondary prevention tool, and secondly, vaccination is developed to prevent long-term infection of the agent,
which is a primary prevention tool, and its transformation into cancer (59). The decisive factor in including HPV in the vaccination program is whether it is cost-effective. The main argument for cost-effectiveness is the years of life gained by preventing deaths (38). There are not many studies conducted on the cost-effectiveness of the HPV vaccine in Turkey. However, according to Sözmen et al. (60), it was seen that administering two doses of vaccine alone is cost-effective, while vaccination without expanding the current screening program is less so. Additionally, a cost-effectiveness study found that HPV vaccines are very cost-effective to administer in the general population (38). Furthermore, in various survey studies conducted in Turkey, the level of awareness of certain groups about HPV infection, screening, and vaccines was investigated. The general public’s knowledge about HPV vaccines was less than their knowledge about cervical cancer and screening, and the most conscious group was found to be health personnel. The group with the least awareness about HPV infection and vaccines is adolescent girls. The results are shown in Table 1 (61-67). In different questionnaires, physicians and students were asked about HPV vaccination-related questions, such as awareness about HPV vaccination, thoughts about their fees, and HPV vaccines being included in the national immunization program was investigated. In general, the results of the surveys with the most supportive responses from students (medical, midwifery, etc.) and physicians are shown in Table 2 where only about 7% of midwifery students are aware of the fact that vaccination may prevent cervical cancer (68-76). Moreover, according to a survey study conducted by Adıgüzel et al. (70), the most common reason for the low HPV vaccination rate in Turkey was that HPV vaccines were not included in the national vaccination program.

It is important to include the HPV vaccine in national vaccination programs to increase herd immunity to HPV (77, 78). This will not only help to eliminate socio-economic inequalities in access to vaccines but also reduce the prevalence of HPV-related diseases. Thus, it will contribute to more efficient use of resources in the health system (77). Early diagnosis of cervical cancer is of great importance for effective treatment (79).
Early diagnosis of HPV-positive individuals by popularizing screening tests may alleviate the problems associated with HPV-related diseases, but it is clear that it is not a sufficient strategy alone for the formation of herd immunity.

 According to a statement made by the Turkish Medical Association in 2019, in cancer screening programs in Turkey, it is seen that the resources and labor spent are not used appropriately, as there are data losses and monitoring problems (80). In another statement by the Turkish Medical Association in October 2021, it was requested that HPV vaccines be added to the national vaccination program free of charge, in addition to national screening, to prevent avoidable diseases and deaths (81). As the spread of the vaccine will reduce HPV-related diseases, it may create an opportunity for more efficient resources and workforce management (82). However, data losses and monitoring problems are a concern for future research and public health. To prevent future cases and reduce the prevalence of HPV-related diseases, the HPV vaccines should be made accessible to everyone, as well as screening tests.

Studies conducted with different populations in different regions of Turkey reveal that participants’ awareness of HPV, cervical cancer, and HPV vaccines is not at a sufficient level, and the prevalence of HPV is similar to other studies in the literature (83-85). A study conducted in Denmark revealed that although there is free access to the vaccine, vaccination rates are affected by the socioeconomic and educational levels of the families (86). This indicates that free access to the vaccine is not a sufficient factor on its own, thus it is also important to work on raising social awareness. As of May 2022, the HPV vaccine is not included in the national vaccination program in Turkey and it is not a vaccine that can be accessed by everyone due to its cost. Although there are requests from time to time to increase awareness of HPV and to include HPV in the national vaccination program with the support of non-governmental organizations and social media campaigns, there has been no development in this direction yet.


Due to its carcinogenic types, HPV occupies a large place in cancer screening, diagnosis, and treatment and creates a demand for prevention methods worldwide (25). The wide spectrum of genital cancers, various clinical presentations, the possibility of malignancy, and the vaccine still not being available to the entire population make it an important issue to deal with, especially in low-income countries (21, 35).

In conclusion, the inclusion of HPV vaccines in vaccination programs by health authorities and policies can encourage community acceptance of HPV vaccines. Especially, the participation of countries that do not have HPV vaccines in their national vaccination programs will be an important initiative in terms of protecting public health. In this context, the inclusion of the HPV vaccine in the national vaccination program of Turkey will contribute to the protection of public health with more efficient resource management.

Ethics Committee Approval: N/A

Informed Consent: N/A

Conflict of Interest: The authors declared no conflict of interest.

Author Contributions: Concept: J.Ö., M.Y., S.K., G.Y., I.İ.Ö., Z.Y.,  Design: J.Ö., M.Y., S.K., G.Y., I.İ.Ö., Z.Y.,  Supervision: J.Ö., M.Y., S.K., G.Y., I.İ.Ö., Z.Y.,  Resources: J.Ö., M.Y., S.K., G.Y., I.İ.Ö., Z.Y., Materials: J.Ö., M.Y., S.K., G.Y., I.İ.Ö., Z.Y.,  Data collection and/or Processing: J.Ö., M.Y., S.K., G.Y., I.İ.Ö., Z.Y., Analysis and/or Interpretation: J.Ö., M.Y., S.K., G.Y., I.İ.Ö., Z.Y., Literature Search: J.Ö., M.Y., S.K., G.Y., I.İ.Ö.,  Writing Manuscript: J.Ö., M.Y., S.K., G.Y., I.İ.Ö., Z.Y.,  Critical Review:  J.Ö., M.Y., S.K., G.Y., I.İ.Ö., Z.Y.

Financial Disclosure: The authors declared that this study received no financial support.

Editor-in-Chief ’s Note: Five of the authors of this article, Janset Özdemir, Mert Yücel, Sarper Kızılkaya, Gizem Yıldırım, and Irmak İrem Özyiğit are members of the editorial board of Turkish Medical Student Journal. However, they did not take place at any stage of the editorial decision of the manuscript. The editors who evaluated this manuscript are from other institutions.


  1. Ahmed HG, Bensumaidea SH, Alshammari FD et al. Prevalence of human papillomavirus subtypes 16 and 18 among Yemeni patients with cervical cancer. Asian Pac J Cancer Prev 2017;18:1543-8.
  2. Centers for Disease Control and Prevention (CDC). Genital HPV infection – Fact Sheet (cited 2022 January 14). Available from: URL:
  3. World Health Organization (WHO). Human papillomavirus (HPV) and cervical cancer (cited 2022 January 14). Available from: URL:
  4. Wigle J, Coast E, Watson-Jones D. Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): health system experiences and prospects. Vaccine 2013;31:3811-7.
  5. Manini I, Montomoli E. Epidemiology and prevention of human papillomavirus. Ann Ig 2018;30(4 Supple 1):28-32.
  6. Handler MZ, Handler NS, Majewski S et al. Human papillomavirus vaccine trials and tribulations: clinical perspectives. J Am Acad Dermatol 2015;73:743-56.
  7. Dunne EF, Park IU. HPV and HPV-associated diseases. Infect Dis Clin North Am 2013;27:765-78.
  8. Hariri S, Unger ER, Sternberg M et al. Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003-2006. J Infect Dis 2011;204:566-73.
  9. Chin-Hong PV, Vittinghoff E, Cranston RD et al. Age-Specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study. J Infect Dis 2004;190:2070-6.
  10. Giuliano AR, Lu B, Nielson CM et al. Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. J Infect Dis 2008;198:827-35.
  11. Patel H, Wagner M, Singhal P et al. Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis 2013;13:39.
  12. Centers for Disease Control and Prevention (CDC). Human Papillomavirus (cited 2022 January 14). Available from: URL:
  13. Hull R, Mbele M, Makhafola T et al. Cervical cancer in low and middle-income countries. Oncol Lett 2020;20:2058-74.
  14. World Health Organization (WHO). Cervical cancer (cited 2022 January 14). Available from: URL:
  15. Kesic V, Poljak M, Rogovskaya S. Cervical cancer burden and prevention activities in Europe. Cancer Epidemiol Biomarkers Prev 2012;21:1423-33.
  16. Öztürker C, Sönmez G. Endometrium ve serviks kanserlerinde görüntüleme. Trd Sem 2015;3:1-11.
  17. Usubütün A, Alemany L, Küçükali T et al. Human papillomavirus types in invasive cervical cancer specimens from Turkey. Int J Gynecol Pathol 2009;28:541-8.
  18. Sapp M, Bienkowska-Haba M. Viral entry mechanisms: human papillomavirus and a long journey from extracellular matrix to the nucleus. FEBS J 2009;276:7206-16.
  19. Pal A, Kundu R. Human papillomavirus E6 and E7: The cervical cancer hallmarks and targets for therapy. Front Microbiol 2020;10:3116.
  20. Nweke MC, Okolo CA, Daous Y et al. Challenges of human papillomavirus infection and associated diseases in low-resource countries. Arch Pathol Lab Med 2018;142:696-9.
  21. Schiffman M, Doorbar J, Wentzensen N et al. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers 2016;2:16086.
  22. Dong Z, Hu R, Du Y et al. Immunodiagnosis and immunotherapeutics based on human papillomavirus for HPV-induced cancers. Front Immunol 2021;11:586796.
  23. Tschandl P, Rosendahl C, Kittler H. Cutaneous human papillomavirus infection: manifestations and diagnosis. Curr Probl Dermatol 2014;45:92-7.
  24. Brianti P, De Flammineis E, Mercuri SR. Review of HPV-related diseases and cancers. New Microbiol 2017;40:80-5.
  25. Hutter JN, Decker CF. Human papillomavirus infection. Dis Mon 2016;62:294-300.
  26. Burd EM, Dean CL. Human papillomavirus. Microbiol Spectr 2016;4.
  27. Candotto V, Lauritano D, Nardone M et al. HPV infection in the oral cavity: epidemiology, clinical manifestations and relationship with oral cancer. Oral Implantol (Rome) 2017;10:209-20.
  28. Johnston MJ, Nigam R. Recent advances in the management of penile cancer. F1000Res (serial online) 2019 April (cited 2022 January 20):8:(9 screens) Available from: URL:
  29. Chelimo C, Wouldes TA, Cameron LD et al. Risk factors for and prevention of human papillomaviruses (HPV), genital warts and cervical cancer. J Infect 2013;66:207-17.
  30. Oumeslakht L, Ababou M, Badaoui B et al. Worldwide genetic variations in high-risk human papillomaviruses capsid L1 gene and their impact on vaccine efficiency. Gene 2021;782:145533.
  31. Polansky H, Itzkovitz E, Javaherian A. Human papillomavirus (HPV): systemic treatment with Gene-Eden-VIR/Novirin safely and effectively clears virus. Drug Des Devel Ther 2017;11:575-83.
  32. Ufuk İ, Muhammed A, Nilay I. Human papilloma virus (hpv) current treatment and protection procedure. Journal of Health Sciences 2017;26:189-92.
  33. Fundakowski CE, Lango M. Considerations in surgical versus non-surgical management of HPV positive oropharyngeal cancer. Cancers Head Neck 2016;1:6.
  34. Kofler B, Laban S, Busch CJ et al. New treatment strategies for HPV-positive head and neck cancer. Eur Arch Otorhinolaryngol 2014;271:1861-7.
  35. Crosbie EJ, Einstein MH, Franceschi S et al. Human papillomavirus and cervical cancer. Lancet 2013;382:889-99.
  36. Symer MM, Yeo HL. Recent advances in the management of anal cancer. F1000Res 2018;7:F1000 Faculty Rev-1572.
  37. Plotkin S, Orenstein W, Offit P, Edwards K. Plotkin’s Vaccines. 7th ed. Elsevier. 2018.p.1-15.
  38. Şahin ÇE. HPV aşısının ulusal aşı programına eklenmesi açısından maliyet-etkililiğinin değerlendirilmesi. İstanbul: İstanbul Univ. 2021.
  39. Murray PR, Rosenthal KS, Pfaller MA. Medical Microbiology. 8th ed. Canada: Elsevier Inc; 2016.p.414.
  40. Brooks GF. Ise Jawetz, Melnick and Adelberg’s Medical Microbiology. 26th ed. The McGraw-Hill; 2013.p.647.
  41. Bonde U, Joergensen JS, Lamont RF et al. Is HPV vaccination in pregnancy safe? Hum Vaccin Immunother 2016;12:1960-4.
  42. Arbyn M, Weiderpass E, Bruni L et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health 2020;8:191-203.
  43. Forman D, de Martel C, Lacey CJ et al. Global burden of human papillomavirus and related diseases. Vaccine 2012;30(Suppl 5):12-23.
  44. Nguyen-Huu NH, Thilly N, Derrough T et al. Human papillomavirus vaccination coverage, policies, and practical implementation across Europe. Vaccine 2020;38:1315-31.
  45. Craciun C, Baban A. “Who will take the blame?”: understanding the reasons why Romanian mothers decline HPV vaccination for their daughters. Vaccine 2012;30:6789-93.
  46. Publications Office of the European Union. European guidelines for quality assurance in cervical cancer screening Second edition – Supplements. (Serial Online) 2015 Aug (cited 2022 January 14) Available from: URL: af5b-2619dd1d5ddc.
  47. Centers for Disease Control and Prevention (CDC). Vaccines for Children Program (VFC) (cited 2022 January 14). Available from: URL:
  48. Medicaid. Program History. (Serial Online) (Cited 2022 January 14) Available from: URL:
  49. Hirth J. Disparities in HPV vaccination rates and HPV prevalence in the United States: a review of the literature. Hum Vaccin Immunother 2019;15:146-55.
  50. Luciani S, Bruni L, Agurto I et al. HPV vaccine implementation and monitoring in Latin America. Salud Publica Mex 2018;60:683-92.
  51. Zou Z, Fairley CK, Ong JJ et al. Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis. Lancet Glob Health 2020;8:1335-44.
  52. Das M. Cervical cancer vaccine controversy in India. Lancet Oncol 2018;19:e84.
  53. Bruni L, Albero G, Serrano B et al. Human Papillomavirus and Related Diseases in the World. Summary Report 17 June 2019. Barcelona (Spain) ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre): 2019 Jun.
  54. Deignan C, Swartz A, Cooper S et al. Stakeholders’ understandings of human papillomavirus (HPV) vaccination in Sub-Saharan Africa: a rapid qualitative systematic review. Vaccines (Basel) 2021;9:496.
  55. Jacobson RM, Agunwamba AA, St Sauver JL et al. The most effective and promising population health strategies to advance human papillomavirus vaccination. Expert Rev Vaccines 2016;15:257-69.
  56. Darden PM, Thompson DM, Roberts JR et al. Reasons for not vaccinating adolescents: National Immunization Survey of Teens, 2008-2010. Pediatrics 2013;131:645-51.
  57. Cocchio S, Bertoncello C, Baldovin T et al. Awareness of HPV and drivers of HPV vaccine uptake among university students: a quantitative, cross-sectional study. Health Soc Care Community 2020;28:1514-24.
  58. Ortiz RR, Smith A, Coyne-Beasley T. A systematic literature review to examine the potential for social media to impact HPV vaccine uptake and awareness, knowledge, and attitudes about HPV and HPV vaccination. Hum Vaccin Immunother 2019;15:1465-75.
  59. Yöntem M, Gümüş A, Abalı R et al. Human papilloma virüs (HPV) varlığının cinsel aktif kadınlarda moleküler metodlarla değerlendirilmesi. Academic Platform Journal of Engineering and Science 2019;7:217-21.
  60. Sözmen K, Tözün M, Baydur H et al. Türkiye’de serviks kanseri taramasının yaygınlaştırılmasının ve insan papilloma virüs aşısı’nın uygulanmasının maliyet etkililiğinin değerlendirilmesi. In: Eskiocak M, İrgil E, Kurt AÖ, Nahcivan N, Etiler N, editors. 17. Ulusal Halk Sağlığı Kongresi. Proceedings of the 17. Ulusal Halk Sağlığı Kongresi; Oct 20-24; Edirne, Türkiye; 2014.p.503-4.
  61. Pınar G, Topuz Ş, An Ş et al. Başkent Üniversitesi Ankara Hastanesi kadın hastalıkları ve doğum polikliniğine başvuran kadınların HPV aşısı ve serviks kanseri ile ilgili bilgi düzeyleri. Türk Jinekolojik Onkoloji Dergisi 2010;1:11-8.
  62. Ozan H, Çetinkaya Demir B, Atik Y et al. Kadın hastalıkları ve doğum polikliniğine başvuran hastaların human papilloma virüs ve hpv aşısı hakkındaki bilgi düzeylerinin belirlenmesi. Uludağ Üniversitesi Tıp Fakültesi Dergisi 2011;37:145-8.
  63. Çetin O, Verit FF, Keskin S et al. Knowledge levels of adolescent girls about human papilloma virus and its vaccine. Turk Arch Pediatr 2014;49:142-7.
  64. Görkem Ü, Toğrul C, İnal HA et al. Knowledge and attitudes of allied health personnel in university hospital related to Human Papilloma Virus and the vaccine. Turk Hij Den Biyol Derg 2015;72:303-10.
  65. Adıgüzel FI, Adıgüzel C, Seyfettinoğlu S et al. HPV awareness and HPV vaccine acceptance among women who apply to the gynecology outpatient clinics at a tertiary referral hospital in the south Mediterranean region of Turkey. Med J Bakirkoy 2016;12:136-9.
  66. Kürtüncü M, Arslan N, Alkan I et al. Knowledge, attitude and behaviors of the mothers of 10-15 year old daughters regarding cervical cancer and HPV vaccine. Journal of Human Sciences 2018;15(2):1072-85.
  67. Çelik P. Hpv aşısı hakkında ailelerin bilgi, tutum ve davranışlarının değerlendirilmesi. Ankara: Ankara Yıldırım Beyazıt Üniv. 2018.
  68. Yıldırım M, Düzovalı Ö, Kanık A et al. Knowledge and Attitudes of The Pediatricians in Turkey Regarding Human Papillomavirus (HPV) Vaccine. J Pediatr Inf 2009;3:62-8.
  69. Çeşmeci Y, Köylü B, Sulaiman J et al. HPV infection and hpv vaccine through the eyes of interns. The Turkish Journal of Gynecologic Oncology 2015;3:85-92.
  70. Adıgüzel A, Akgül S, Düzçeker Y et al. Çocuk hekimlerinin human papilloma virus aşıları hakkındaki bilgi ve eğilimleri. Çocuk Sağlığı Hastalıkları Dergisi 2018;61:53-8.
  71. Kızılca Çakaloz D, Öztürk G, Çoban A et al. Determination of the Knowledge and Opinions of Midwifery Students about Cervical Cancer and Human Papilloma Virus Vaccination. Journal of Adnan Menderes University Health Sciences Faculty 2018;2:55-64.
  72. Aydın B. HPV aşısı hakkında aile hekimlerinin bilgi düzeyleri, tutum ve davranışlarının değerlendirilmesi. Ankara: Ankara Yıldırım Beyazıt Üniv. 2019.
  73. Başlı M, Aksu H, Toptaş B. Knowledge and views about human papilloma virus and hpv vaccine of school of health high students who studyıng at a unıversıty. Journal of Ankara Health Sciences 2019;1:1-17.
  74. Erdem HA, Işıkgöz Taşbakan M, Şanlıdağ G et al. Aşı oluyoruz, peki gerçekten biliyor muyuz?: HPV aşısı olan tıp fakültesi öğrencilerinin HPV infeksiyonu ve aşısı ile ilgili bilgilerinin değerlendirilmesi. FLORA 2020;25:62-8.
  75. Emre N, Özşahin A, Edirne T. Pamukkale University Medical Faculty Students’ Knowledge Level of Human Papilloma Virus Infection and Vaccine. Euras J Fam Med 2020;9:42-50.
  76. Taşar S, Bal Yüksel E, Sağcan D et al. Knowledge and Attitudes of Pediatricians towards The Human Papilloma Virus Vaccines. Forbes J Med 2021;2:19-24.
  77. Castle PE, Maza M. Prophylactic HPV vaccination: past, present, and future. Epidemiol Infect 2016;144:449-68.
  78. Spinner C, Ding L, Bernstein DI et al. Human papillomavirus vaccine effectiveness and herd protection in young women. Pediatrics 2019;143:e20181902.
  79. Centers for Disease Control and Prevention (CDC). Cancers Caused by HPV (cited 2022 January 14). Available from: URL:
  80. Türk Tabipleri Birliği (TTB). Kanser taramalarında sorunlar giderilemiyor (cited 2022 January 14). Available from: URL:
  81. Türk Tabipleri Birliği (TTB). TTB, HPV Aşılarının Ulusal Aşı Takvimine Eklenmesini İstedi (cited 2022 January 14). Available from: URL:
  82. Ankara Tabip Odası. HPV aşısıyla binlerce kadının hayatı kurtulabilir (cited 2022 January 14). Available from: URL:
  83. Aynaci G, Guksu Z. Awareness of HPV and HPV vaccination in undergraduate students in the North West region of Turkey: near future outlook. J Infect Dev Ctries 2019;13:516-25.
  84. Sahin HG, Kolusari A, Guducuoglu H. Prevalence of high risk human papillomavirus (HPV) infection and abnormal cervical cytology and knowledge about HPV vaccine in Eastern Turkey. Eur J Gynaecol Oncol 2017;38:241-4.
  85. Özdemir S, Akkaya R, Karaşahin KE. Analysis of community-based studies related with knowledge, awareness, attitude, and behaviors towards HPV and HPV vaccine published in Turkey: a systematic review. J Turk Ger Gynecol Assoc 2020;21:111-23.
  86. Slåttelid Schreiber SM, Juul KE, Dehlendorff C et al. Socioeconomic predictors of human papillomavirus vaccination among girls in the Danish childhood immunization program. J Adolesc Health 2015;56:402-7.